Interdisciplinary collaboration
Access to the resources of Stanford University -- including the Schools of Engineering, Law, Business, Humanities & Sciences and Education
Excellence in Scientific Discovery
The Institute's comprehensive investigations extend from the earliest phase of basic discovery to the development of new cancer diagnostics, treatment protocols and prevention strategies
Research Programs
Basic, clinical and translational studies into the biology of cancer and the factors that contribute to its onset and growth.
Shared Resources
The most sophisticated technologies and research protocols are offered to SCI members through a number of core facilities.
Key Initiatives
Inter-disciplinary teams of collaborative investigators partner to foster discovery, application and translation of scientific knowledge.
Institute Membership
Scientists and physicians from a wide range of disciplines, all dedicated to reducing the burden of cancer.
News & Publications
Publications, press releases and news are shared with scientists, physicians, patients and friends of the Institute.
Funding Opportunities
Internal and external sources of support for both established cancer research programs and promising new ideas.
Clinical Trial Support
The Cancer Clinical Trials Office provides regulatory and administrative services to SCI members conducting clinical trials.
Training Opportunities
Education and professional development designed to train the next generation of cancer researchers and physicians.
National Cancer Institute Designation
In addition to providing grants and other support to cancer researchers at institutions around the country, the National Cancer Institute employs scientists who conduct basic, clinical, and population-based research, including the study of rare cancers and the translation of laboratory findings to the clinic.
News & Publications
-
Understanding ‘chemo brain’
Three types of cells in the brain’s white matter show interwoven problems during the cognitive dysfunction that follows treatment with the cancer drug methotrexate, Stanford neuroscientists have found.
-
No survival benefit with new cancer drug
Cisplatin chemotherapy can bring lasting adverse health effects, but a new, presumably less-toxic alternative is not as effective at promoting survival, according to a large, Stanford-led trial.
-
Study: Anti-CD47 cancer therapy safe
An immunotherapy conceived at Stanford appeared safe in an early clinical trial. Half of the participants responded positively to the treatment, aimed at triggering macrophages to engulf cancer cells, the researchers reported.
